The rise and fall of HbA1c as a risk marker for diabetes complications

Diabetologia

Volumn 55, Issue 8, 2012, Pages 2089-2091

  Kilpatrick, E S ^a,b  

^a HULL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Complications; Glycaemia; HbA1c; Microvascular; Variability

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

CARDIOVASCULAR RISK; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE REGISTRY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; JAPAN; MICROANGIOPATHY; POSTPRANDIAL STATE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 84866422656     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2610-5     Document Type: Review

References (16)

1. 1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia. doi:10.1007/s00125-012-2572-7
2. Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486-1490
3. Kilpatrick ES, Rigby AS, Atkin SL (2009) Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32:1901
4. Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra J B L, DeVries JH (2009) Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 52:2229-2232
5. Home PD (2005) Contributions of basal and post-prandial hyperglycaemia to micro-and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 21:989-998
6. Raz I, Wilson P W F, Strojek K et al (2009) Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32:381-386
7. Kilpatrick ES, Rigby AS, Atkin SL (2008) A1C variability and the risk of microvascular complications in type 1 diabetes. Diabetes Care 31:2198-2202
8. Wadèn J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH, Finnish Diabetic Nephropathy Study Group (2009) A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 58:2649-2655
9. Marcovecchio ML, Dalton RN, Chiarelli F, Dunger DB (2011) A1C variability as an independent risk factor for microalbuminuria in young people with type 1 diabetes. Diabetes Care 34:1011-1013
10. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563-2569
11. Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653
12. Ihnat M, Thorpe J, Ceriello A (2007) Hypothesis: the žmetabolic memory', the new challenge of diabetes. Diabet Med 24:582-586
13. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 329:977-986
14. Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412
15. The Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol 116:874-886
16. Bolen SD, Bricker E, Samuels TA et al (2009) Factors associated with intensification of oral diabetes medications in primary care provider-patient dyads: a cohort study. Diabetes Care 32:25-31